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Abstract
Introduction: The levonorgestrel-releasing intra-uterine device (Mirena®) is an effective, long
term form of contraception that leads to a significant reduction of menstrual bleeding among
majority of women. However, irregular bleeding is quite common in initial Mirena® users and may
thereby mask underlying cervical pathology.
Case presentation: Two women with cervical cancer and a Mirena® initially presented with
irregular bleeding, posing a diagnostic pitfall which resulted in doctor and patient delay.
Conclusion: Proper evaluation of irregular vaginal bleeding, including cervical cytology, should be
a prerequisite among all women opting for a Mirena® and must be repeated in case of persisting
symptoms.
Introduction
The Mirena®  (levonorgestrel-releasing intra-uterine
device) has proven to be an effective, long term and
reversible form of contraception that leads to a significant
reduction (90%) of menstrual bleeding among the major-
ity of women [1]. It is thereby also an alternative to hys-
terectomy and endometrial ablation for menorrhagia,
including among perimenopausal women [2]. However,
since irregular bleeding is quite common in initial
Mirena® users, this symptom may mask underlying cervi-
cal pathology as presented below.
Case 1
A 40-year old nulligravida was referred to our outpatient
clinic because of menorrhagia and irregular bleeding since
2 years, unresponsive to oral contraceptives. Her general
practitioner obtained a Papanicolaou (Pap) smear at ini-
tial presentation of symptoms, which revealed no abnor-
malities. Inspection of the cervix showed no lesions,
polyps or unusual bleeding. By vaginal ultrasound an
intramural fibroid was seen in the fundus, measuring 4,5
cm × 4,5 cm and no further uterine anomalies. The next
day, a Mirena® was inserted. She returned to our clinic 2
weeks later due to abdominal cramping. The Mirena® was
in place. She was treated with antibiotics and painkillers
on a presumptive diagnosis of pelvic inflammatory dis-
ease. Two months later at follow-up, the Mirena® was still
in place and irregular bleeding continued. As this is a
common symptom in the first 3 months of Mirena® use,
she was reassured and instructed to make a new appoint-
ment if the bleeding were to persist.
Seven months after initial referral, she was seen for a cyst
of Bartholin. During follow-up of the cyst, inspection by
speculum revealed inflammation of the cervix. A Pap
smear was performed, and during colposcopic examina-
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tion, a lesion suspicious for neoplasia with abnormal ves-
sels was seen. Two biopsies were taken and revealed a
moderately differentiated squamous cell carcinoma. The
Pap smear was reported as squamous cell carcinoma.
Revision of the initial smear showed that due to blood
staining it was difficult to interpret, but in retrospect it was
suspect of malignancy. Clinical staging allocated our
patient to cervical cancer stage IB. She was referred to a
centre for Oncology for a radical hysterectomy with pelvic
node dissection.
Case 2
A 29-year-old woman was referred by her general practi-
tioner 2 months after delivery of her first child for inser-
tion of a Mirena®. Her medical history revealed no prior
gynaecological problems and she had no history of abnor-
mal cervical cytology. Examination by speculum and
ultrasound prior to insertion of the Mirena® revealed no
abnormalities. Due to ongoing irregular bleeding and
abdominal pains since insertion, the Mirena®  was
removed several months later and oral contraception was
prescribed. The irregular bleeding was attributed to the
Mirena® and no Pap smear was obtained in this period.
Nine months after initial referral, she was referred again
by her general practitioner due to persisting irregular
bleeding and rebound tenderness during bimanual palpa-
tion. An ulcerative lesion on the cervix was seen by specu-
lum, suspect for malignancy. Cervical cytology revealed
moderate dysplasia, biopsies a micro-invasive squamous
cell carcinoma of the cervix. Clinical staging allocated her
to stage IIA cervical cancer. Assessment of new biopsies
revealed adenosquamous carcinoma. She was also
referred to a centre for Oncology for a radical hysterec-
tomy with pelvic node dissection. During surgery, how-
ever, the procedure was aborted due to tumour extension
into the vesicouterine fold. Lymph nodes were negative
and she was treated by radiotherapy with brachytherapy.
Discussion
The cases presented above both illustrate the doctor's
delay caused by treating young women presenting with
vaginal bleeding with a Mirena® without proper evalua-
tion of its cause. Persistence of symptoms was attributed
to the Mirena®. Results of prior long-term studies on cervi-
cal cytology in women using a Mirena® have shown that
there is no increased incidence of cervical intraepithelial
neoplasia [3,4]. Nevertheless, delayed diagnosis of cervi-
cal neoplasia among women with a Mirena® may be more
common than presumed, considering the fact that irregu-
lar bleeding is almost inherent to initial Mirena® use.
The second pitfall is the limited sensitivity of a Pap smear,
varying from 50–80% depending on the study and type of
cytology assessment used [5,6]. Among the 80 women
diagnosed with cervical cancer at our clinic between 1999
and 2004, the first patient presented above was the only
one with a screening history showing no abnormal cytol-
ogy and on revision a Pap smear suspect for malignancy
(unpublished data). Similar results of a misinterpreted
Pap test have been published by others [7-10]. It may
seem common sense to scrutinise a normal result if our
clinical findings do not correlate, but it becomes more
complicated if no evident cervical anomalies are seen. Fur-
thermore, as our first case illustrates, a Pap smear should
be repeated regardless of prior findings if new symptoms
develop or irregular bleeding persists. It is therefore ques-
tionable whether it was correct to attribute the ongoing
irregular bleeding to the fibroid alone since no new cervi-
cal cytology was obtained at time of initial referral.
In conclusion, we suggest that proper evaluation of irreg-
ular bleeding including cervical cytology should be per-
formed among all women opting for a Mirena®, and must
be repeated in case of persisting symptoms.
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